Dishman Carbogen Amcis Limited (NSE:DCAL)
India · Delayed Price · Currency is INR | Market Cap | 27.34B -34.8% |
| Revenue (ttm) | 29.01B +0.2% |
| Net Income | 161.60M -84.5% |
| EPS | 1.03 -84.7% |
| Shares Out | 156.78M |
| PE Ratio | 168.99 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 122,644 |
| Open | 178.50 |
| Previous Close | 176.99 |
| Day's Range | 173.20 - 178.50 |
| 52-Week Range | 128.50 - 321.95 |
| Beta | 0.61 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About Dishman Carbogen Amcis
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and... [Read more]
Financial Performance
In fiscal year 2026, Dishman Carbogen Amcis's revenue was 29.32 billion, an increase of 8.13% compared to the previous year's 27.12 billion. Earnings were 974.50 million, an increase of 2907.72%.
Financial StatementsNews
Dishman Carbogen Amcis shares rise nearly 3% on June 30 after Swiss subsidiary commissions 1.2 MW solar power plant; here's why
Dishman Carbogen Amcis shares gained nearly 3% in early trade on Tuesday, June 30, after the company announced that its wholly-owned Swiss subsidiary, CARBOGEN AMCIS AG, has commissioned a 1.2…
Dishman Carbogen clears US FDA inspection at Naroda facility with no observations
Dishman Carbogen Amcis Ltd has announced the successful completion of a scheduled US FDA inspection at its Naroda facility in Ahmedabad. The inspection, which was planned from June 9 to June 13, 2025,...
Dishman Carbogen shares in focus after Swiss subsidiary signs CHF 25 million co-investment agreement
Shares of Dishman Carbogen Amcis Ltd. could see increased investor interest after its Swiss subsidiary, CARBOGEN AMCIS AG, announced a strategic co-investment exceeding CHF 25 million with a key Japan...
Dishman Carbogen Amcis shares surge over 11% as company swings to profit in Q4, EBITDA margin doubles
Shares of Dishman Carbogen Amcis Ltd jumped 11.12% to ₹244.50 on Thursday after the company reported a turnaround in its financial performance for the March quarter (Q4 FY25). The stock was among the ...
Dishman Carbogen shares surge 5% after arm gets drug manufacturing licence In China
Dishman Carbogen Amcis Ltd. witnessed a 5% jump in its share price after announcing a significant regulatory milestone. Its wholly owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has secured a D...
Dishman Carbogen Amcis subsidiary receives drug manufacturing license in China
Dishman Carbogen Amcis Ltd. has announced that its wholly owned subsidiary, CARBOGEN AMCIS (Shanghai) Co. Ltd., has received a Drug Manufacturing License from the National Medical Products Administrat...
Dishman Carbogen Amcis shares jump nearly 2% after board approves Rs 50 crore debenture issuance
Shares of Dishman Carbogen Amcis Ltd gained 1.90% to ₹210.22 on Wednesday after the company’s board approved the issuance of rated, listed, senior, secured, redeemable, taxable non-convertible debentu...
Dishman Carbogen subsidiary successfully completes Swissmedic inspection of its Vionnaz facility
CARBOGEN AMCIS AG, a subsidiary of Dishman Carbogen Amcis Limited, has announced the successful completion of a Swissmedic inspection at its Vionnaz facility in Switzerland. This achievement reaffirms...